tiprankstipranks
Trending News
More News >
SAGE Therapeutics, Inc. (US) (SAGE)
:SAGE
US Market

SAGE Therapeutics (SAGE) Stock Forecast & Price Target

Compare
933 Followers
See the Price Targets and Ratings of:

SAGE Analyst Ratings

Hold
14Ratings
Hold
2 Buy
11 Hold
1 Sell
Based on 14 analysts giving stock ratings to
SAGE
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SAGE Stock 12 Month Forecast

Average Price Target

$8.75
▲(34.00%Upside)
Based on 14 Wall Street analysts offering 12 month price targets for SAGE Therapeutics in the last 3 months. The average price target is $8.75 with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a 34.00% change from the last price of $6.53.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","11":"$11","18":"$18","7.5":"$7.5","14.5":"$14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7.5,11,14.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.48,7.827692307692308,8.175384615384615,8.523076923076923,8.87076923076923,9.218461538461538,9.566153846153846,9.913846153846155,10.26153846153846,10.60923076923077,10.956923076923076,11.304615384615385,11.652307692307692,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.48,7.577692307692308,7.6753846153846155,7.773076923076923,7.870769230769231,7.968461538461539,8.066153846153846,8.163846153846155,8.261538461538462,8.35923076923077,8.456923076923077,8.554615384615385,8.652307692307692,{"y":8.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.48,7.28923076923077,7.098461538461539,6.907692307692308,6.716923076923077,6.526153846153846,6.335384615384616,6.144615384615385,5.953846153846154,5.763076923076923,5.572307692307692,5.381538461538462,5.190769230769231,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.9,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.28,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.11,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.03,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.76,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.3,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$12.00Average Price Target$8.75Lowest Price Target$5.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on SAGE
Tazeen AhmadBank of America Securities
Bank of America Securities
$5
Sell
-23.43%
Downside
Reiterated
05/19/25
Bank of America Securities Sticks to Their Sell Rating for SAGE Therapeutics (SAGE)
J.P. Morgan Analyst forecast on SAGE
Anupam RamaJ.P. Morgan
J.P. Morgan
$9$11
Hold
68.45%
Upside
Reiterated
05/06/25
J.P. Morgan Keeps Their Hold Rating on SAGE Therapeutics (SAGE)
Truist Financial Analyst forecast on SAGE
Joon LeeTruist Financial
Truist Financial
Hold
Reiterated
05/05/25
SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial
H.C. Wainwright Analyst forecast on SAGE
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$12
Hold
83.77%
Upside
Reiterated
04/30/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), SAGE Therapeutics (NASDAQ: SAGE) and Repligen (NASDAQ: RGEN)
Needham Analyst forecast on SAGE
Ami FadiaNeedham
Needham
Hold
Reiterated
04/30/25
Cautious Hold Rating on SAGE Therapeutics Amid Uncertain Growth Prospects
Wedbush
$6
Hold
-8.12%
Downside
Reiterated
04/30/25
Wedbush Remains a Hold on SAGE Therapeutics (SAGE)
Piper Sandler Analyst forecast on SAGE
David AmsellemPiper Sandler
Piper Sandler
$9
Buy
37.83%
Upside
Reiterated
04/30/25
Piper Sandler Sticks to Their Buy Rating for SAGE Therapeutics (SAGE)
Scotiabank Analyst forecast on SAGE
George FarmerScotiabank
Scotiabank
$12
Buy
83.77%
Upside
Reiterated
04/30/25
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (NASDAQ: SAGE) and BridgeBio Pharma (NASDAQ: BBIO)
TD Cowen Analyst forecast on SAGE
Ritu BaralTD Cowen
TD Cowen
$9
Hold
37.83%
Upside
Reiterated
04/29/25
Cautious Hold Rating on SAGE Therapeutics Amid Financial Pressures and Strategic Uncertainties
Leerink Partners Analyst forecast on SAGE
Marc GoodmanLeerink Partners
Leerink Partners
$8
Hold
22.51%
Upside
Reiterated
04/29/25
SAGE Therapeutics: Hold Rating Maintained Amid Steady Growth and Strategic Uncertainties
Canaccord Genuity Analyst forecast on SAGE
Sumant KulkarniCanaccord Genuity
Canaccord Genuity
$8
Hold
22.51%
Upside
Reiterated
04/29/25
SAGE Therapeutics: Hold Rating Amid Uncertainty in Sales Growth and Strategic Developments
RBC Capital Analyst forecast on SAGE
Brian AbrahamsRBC Capital
RBC Capital
$7
Hold
7.20%
Upside
Reiterated
04/29/25
Analysts Conflicted on These Healthcare Names: Universal Health (NYSE: UHS), SAGE Therapeutics (NASDAQ: SAGE) and Henry Schein (NASDAQ: HSIC)
Mizuho Securities Analyst forecast on SAGE
Uy EarMizuho Securities
Mizuho Securities
$9
Hold
37.83%
Upside
Reiterated
04/29/25
SAGE Therapeutics (SAGE) Gets a Hold from Mizuho Securities
Morgan Stanley Analyst forecast on SAGE
Vikram PurohitMorgan Stanley
Morgan Stanley
$9
Hold
37.83%
Upside
Reiterated
04/21/25
Morgan Stanley Keeps Their Hold Rating on SAGE Therapeutics (SAGE)
Robert W. Baird Analyst forecast on SAGE
Joel BeattyRobert W. Baird
Robert W. Baird
$9$7
Hold
7.20%
Upside
Reiterated
02/12/25
Sage Therapeutics price target lowered to $7 from $9 at BairdSage Therapeutics price target lowered to $7 from $9 at Baird
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on SAGE
Tazeen AhmadBank of America Securities
Bank of America Securities
$5
Sell
-23.43%
Downside
Reiterated
05/19/25
Bank of America Securities Sticks to Their Sell Rating for SAGE Therapeutics (SAGE)
J.P. Morgan Analyst forecast on SAGE
Anupam RamaJ.P. Morgan
J.P. Morgan
$9$11
Hold
68.45%
Upside
Reiterated
05/06/25
J.P. Morgan Keeps Their Hold Rating on SAGE Therapeutics (SAGE)
Truist Financial Analyst forecast on SAGE
Joon LeeTruist Financial
Truist Financial
Hold
Reiterated
05/05/25
SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial
H.C. Wainwright Analyst forecast on SAGE
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$12
Hold
83.77%
Upside
Reiterated
04/30/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), SAGE Therapeutics (NASDAQ: SAGE) and Repligen (NASDAQ: RGEN)
Needham Analyst forecast on SAGE
Ami FadiaNeedham
Needham
Hold
Reiterated
04/30/25
Cautious Hold Rating on SAGE Therapeutics Amid Uncertain Growth Prospects
Wedbush
$6
Hold
-8.12%
Downside
Reiterated
04/30/25
Wedbush Remains a Hold on SAGE Therapeutics (SAGE)
Piper Sandler Analyst forecast on SAGE
David AmsellemPiper Sandler
Piper Sandler
$9
Buy
37.83%
Upside
Reiterated
04/30/25
Piper Sandler Sticks to Their Buy Rating for SAGE Therapeutics (SAGE)
Scotiabank Analyst forecast on SAGE
George FarmerScotiabank
Scotiabank
$12
Buy
83.77%
Upside
Reiterated
04/30/25
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (NASDAQ: SAGE) and BridgeBio Pharma (NASDAQ: BBIO)
TD Cowen Analyst forecast on SAGE
Ritu BaralTD Cowen
TD Cowen
$9
Hold
37.83%
Upside
Reiterated
04/29/25
Cautious Hold Rating on SAGE Therapeutics Amid Financial Pressures and Strategic Uncertainties
Leerink Partners Analyst forecast on SAGE
Marc GoodmanLeerink Partners
Leerink Partners
$8
Hold
22.51%
Upside
Reiterated
04/29/25
SAGE Therapeutics: Hold Rating Maintained Amid Steady Growth and Strategic Uncertainties
Canaccord Genuity Analyst forecast on SAGE
Sumant KulkarniCanaccord Genuity
Canaccord Genuity
$8
Hold
22.51%
Upside
Reiterated
04/29/25
SAGE Therapeutics: Hold Rating Amid Uncertainty in Sales Growth and Strategic Developments
RBC Capital Analyst forecast on SAGE
Brian AbrahamsRBC Capital
RBC Capital
$7
Hold
7.20%
Upside
Reiterated
04/29/25
Analysts Conflicted on These Healthcare Names: Universal Health (NYSE: UHS), SAGE Therapeutics (NASDAQ: SAGE) and Henry Schein (NASDAQ: HSIC)
Mizuho Securities Analyst forecast on SAGE
Uy EarMizuho Securities
Mizuho Securities
$9
Hold
37.83%
Upside
Reiterated
04/29/25
SAGE Therapeutics (SAGE) Gets a Hold from Mizuho Securities
Morgan Stanley Analyst forecast on SAGE
Vikram PurohitMorgan Stanley
Morgan Stanley
$9
Hold
37.83%
Upside
Reiterated
04/21/25
Morgan Stanley Keeps Their Hold Rating on SAGE Therapeutics (SAGE)
Robert W. Baird Analyst forecast on SAGE
Joel BeattyRobert W. Baird
Robert W. Baird
$9$7
Hold
7.20%
Upside
Reiterated
02/12/25
Sage Therapeutics price target lowered to $7 from $9 at BairdSage Therapeutics price target lowered to $7 from $9 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering SAGE Therapeutics

1 Month
xxx
Success Rate
12/20 ratings generated profit
60%
Average Return
+0.27%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +0.27% per trade.
3 Months
xxx
Success Rate
14/20 ratings generated profit
70%
Average Return
+2.60%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +2.60% per trade.
1 Year
Tazeen AhmadBank of America Securities
Success Rate
10/20 ratings generated profit
50%
Average Return
-5.95%
reiterated a sell rating 17 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -5.95% per trade.
2 Years
xxx
Success Rate
7/20 ratings generated profit
35%
Average Return
-19.85%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 35.00% of your transactions generating a profit, with an average return of -19.85% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SAGE Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
3
3
3
2
1
Buy
1
1
1
1
1
Hold
20
21
19
23
14
Sell
1
0
1
1
2
Strong Sell
0
0
0
0
0
total
25
25
24
27
18
In the current month, SAGE has received 2 Buy Ratings, 14 Hold Ratings, and 2 Sell Ratings. SAGE average Analyst price target in the past 3 months is 8.75.
Each month's total comprises the sum of three months' worth of ratings.

SAGE Financial Forecast

SAGE Earnings Forecast

Next quarter’s earnings estimate for SAGE is -$0.95 with a range of -$1.07 to -$0.80. The previous quarter’s EPS was -$1.01. SAGE beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year SAGE has Outperformed its overall industry.
Next quarter’s earnings estimate for SAGE is -$0.95 with a range of -$1.07 to -$0.80. The previous quarter’s EPS was -$1.01. SAGE beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year SAGE has Outperformed its overall industry.

SAGE Sales Forecast

Next quarter’s sales forecast for SAGE is $16.77M with a range of $15.00M to $19.60M. The previous quarter’s sales results were $14.06M. SAGE beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year SAGE has Outperformed its overall industry.
Next quarter’s sales forecast for SAGE is $16.77M with a range of $15.00M to $19.60M. The previous quarter’s sales results were $14.06M. SAGE beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year SAGE has Outperformed its overall industry.

SAGE Stock Forecast FAQ

What is SAGE’s average 12-month price target, according to analysts?
Based on analyst ratings, SAGE Therapeutics, Inc. (US)’s 12-month average price target is 8.75.
    What is SAGE’s upside potential, based on the analysts’ average price target?
    SAGE Therapeutics, Inc. (US) has 34.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SAGE a Buy, Sell or Hold?
          SAGE Therapeutics, Inc. (US) has a consensus rating of Hold which is based on 2 buy ratings, 11 hold ratings and 1 sell ratings.
            What is SAGE Therapeutics, Inc. (US)’s price target?
            The average price target for SAGE Therapeutics, Inc. (US) is 8.75. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $12.00 ,the lowest forecast is $5.00. The average price target represents 34.00% Increase from the current price of $6.53.
              What do analysts say about SAGE Therapeutics, Inc. (US)?
              SAGE Therapeutics, Inc. (US)’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of SAGE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis